Citigroup
PRME icon

Citigroup’s Prime Medicine PRME Stock Holding History

Citigroup’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$164K Sell
47,232
-3,997
-8% -$15.2K ﹤0.01% 4080
2025
Q4 		$178K Buy
51,229
+46,078
+895% +$205K ﹤0.01% 4058
2025
Q3 		$28.5K Sell
5,151
-29,608
-85% -$120K ﹤0.01% 4687
2025
Q2 		$85.9K Sell
34,759
-7,543
-18% -$11.6K ﹤0.01% 4484
2025
Q1 		$84.2K Sell
42,302
-5,129
-11% -$13.1K ﹤0.01% 4688
2024
Q4 		$138K Sell
47,431
-640
-1% -$2.25K ﹤0.01% 4657
2024
Q3 		$186K Buy
48,071
+30,560
+175% +$142K ﹤0.01% 4388
2024
Q2 		$90K Sell
17,511
-26,459
-60% -$160K ﹤0.01% 4264
2024
Q1 		$308K Buy
43,970
+33,035
+302% +$251K ﹤0.01% 3826
2023
Q4 		$96.9K Sell
10,935
-45,258
-81% -$349K ﹤0.01% 4215
2023
Q3 		$536K Buy
56,193
+42,032
+297% +$546K ﹤0.01% 3005
2023
Q2 		$207K Buy
14,161
+5,302
+60% +$74K ﹤0.01% 3882
2023
Q1 		$109K Buy
8,859
+5,272
+147% +$85.9K ﹤0.01% 3980
2022
Q4 		$66.6K Buy
+3,587
New +$64.8K ﹤0.01% 4187

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citigroup's PRME Position: Q1 2026 in Review

Citigroup reduced its Prime Medicine (PRME) stake by 7.8% in Q1 2026, selling an estimated $15.2K and leaving 47,232 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #4080.

Citigroup first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $536K in Q3 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Citigroup held 47,232 shares of Prime Medicine worth $164K as of Q1 2026.
  • Citigroup sold 3,997 Prime Medicine shares in Q1 2026, an estimated $15.2K.
  • Prime Medicine made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4080 holding.
  • Citigroup first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Citigroup's Prime Medicine position peaked at $536K in Q3 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.